<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yale, Sophie Elizabeth</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Prednisolone in COPD: the overlooked harm</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">155-155</style></pages><doi><style  face="normal" font="default" size="100%">10.3399/bjgp24X736809</style></doi><volume><style face="normal" font="default" size="100%">74</style></volume><issue><style face="normal" font="default" size="100%">741</style></issue><abstract><style  face="normal" font="default" size="100%">Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the world, with the mainstay of treatment instigated in primary care.1Prednisolone is used in the management of COPD exacerbations. The use of steroids is associated with a higher risk of bone fractures and osteoporosis-related events.2,3 While …</style></abstract></record></records></xml>